SHIRE PHARMACEUTICALS LLC for SHIRE PHARMACEUTICALS LLC
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - Affordable Care Act Medicaid Expansion - Medicare IVIG Access Act Reauthorization HR 3172 - Medicare Part D
| Lobbyist | Covered position, as disclosed |
|---|---|
| ENGEL BURNS | — |
| JED PERRY | — |
Taxation/Internal Revenue Code TAX
Orphan drug tax credit HR 1: An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018 (Tax Cuts and Jobs Act)
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARK LENKER | — |
| JED PERRY | — |
Health Issues HCR
340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing
| Lobbyist | Covered position, as disclosed |
|---|---|
| ENGEL BURNS | — |
| MARK LENKER | — |
| JED PERRY | — |
Pharmacy PHA
ADHD Awareness *Drug Values -Binge Eating Disorder awareness -DEA processes and re-exportation -FDA Funding -Medicaid rare disease patient access to therapy Patient access to therapy, including Medicaid, Medicare, and insurance. -Orphan Drug Act regulations -HR 1628 - American Health Care Act of 2017 American Health Care Act of 2017/Better Care Reconciliation Act (H.R. 1628), including patient access, needs for rare disease patients, coverage issues, pre-existing conditions, lifetime and annual caps, essential health benefits, Medicaid, reimbursement, and insurance. -PDUFA Reauthorization The Food and Drug Act Reauthorization Act (FDARA) of 2017 (H.R. 2430 and S. 934), including the PDUFA Reauthorization, RACE for Children Act, Right-to-Try, expanded access, clinical superiority standards, drug access and values, off-label communications, pediatric labeling and generic drugs, and drug importation. -Expanded Access -NIH funding, including expansion for rare diseases -Rare Disease awareness -RACE for Children Act (S. 456 and H.R. 1231) -Right to Try legislation (S. 204, H.R. 878, and H.R. 2368) -Pharmaceutical Information Exchange Act (H.R. 2026) -Drug Diversion and Counterfeit Crackdown Act of 2017 (H.R. 2376) -Medical Product Communications Act (H.R. 1703) -Newborn Screening -Study eligibilities for DOD PRMRP
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARK LENKER | — |
| JED PERRY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.